444 PATENT ABSTRACTS

Hybridomas which produce monoclonal anti- residues that are not part of the intramolecular bodies specific to an abnormal branched deter- disulfide bond can be replaced by other amino minant of a synthetic glycolipid antigen and acid residues or be bonded to substituent methods of use of the monoclonal antibodies, moieties. The polypeptides can be a monomeric

or multimeric material containing an intra- molecular, intrapolypeptide and/or an intra- molecular, interpolypeptide cystine disulfide

4885359 bond.

M E T H O D F O R T H E P U R I F I C A T I O N O F L P F - H A

Akihiro Ginnaga, Tsukasa Nishihara, Tetsuo 4886742 Kawahara, Sadao Susumi, Hiroshi Mizokami, Mitsuo Sakoh, Kumamoto, Japan assigned to E N Z Y M E I M M U N O A S S A Y F O R Juridical Foundation The Chemo-Sero- D E T E C T I N G H I V A N T I G E N S I N Therapeutic Research Institute H U M A N S E R A

Improved method for the purification of LPF- Kenneth Kortright, David E Hofheinz, Meryl HA (Leucocytosis promoting factor hemag- Forman, Song Lee, Paulette Smariga, Candie S glutinin) on industrial scale which comprises Stoner assigned to Coulter Corporation contacting a LPF-HA-containing solution from culture media of Bordetella pertussis with a o51- A solid-phase immunoassay is provided for lulose sulfate gel, a crosslinked polysaccharide determination of HIV antigens in human phys- sulfate gel, or a polysaccharide gel chemically iological fluid. The immunoassay is charac- bound with dextran sulfate, thereby adsorbing terized by the coating of a solid substrate with a LPF-HA on the gel, and then eluting LPF-HA unique monoclonal antibody which recognizes a from the gel. Said method can give a highly common antigenic determinant of a group of purified LPF-HA which does not contain any HIV core antigens and no HIV envelope anti- other proteins, lipid, saccharides, etc. and fur- gens of HIV. The test sample preferably also is ther undesirable endotoxin, and hence can be subjected to a lysing reagent prior to the incuba- used for producing various reagents, medicines tion for uniformly dispersing antigens which and pertussis vaccine, may be present in the test sample.

4886663 4886745

S Y N T H E T I C H E A T - S T A B L E M O N O C L O N A L A N T I B O D Y E N T E R O T O X I N P O L Y P E P T I D E S P E C I F I C F O R H U M A N B A S A L

O F E S C H E R I C H I A C O L I A N D C E L L S U R F A C E A N T I G E N M U L T I M E R S T H E R E O F

Vera Morhenn assigned to Syntex Inc Richard Houghten assigned to Scripps Clinic and Research Foundation The present invention is concerned with novel

monoclonal antibodies specific for an antigenic A synthetic polypeptide having at least about site on a protein characteristic of a human basal 10~o of the immunological activity of biologic cell and a malignant squamous cell. The anti- beat-stable enterotoxin of E. coli. The synthetic bodies do not bind to mesenchymal cells such as polypeptide includes at least 14 amino acids in fibroblasts and endothelial cells. The protein on the sequence, from amino-terminus to carboxy- the cell surface which binds to one of the anti- terminus, represented by the formula: bodies has a molecular weight of about 120,000 CysCysGluLeuCysCysTyr as determined by one dimensional gel elec- (Asn)ProAlaCysAla(Thr) GlyCysAsn(Tyr) trophoresis. The antibodies find use in wherein the amino acid in parentheses may diagnostic methods such as the detection of replace the immediately preceding amino acid malignant cells, e.g., the detection of residual residue, and at least one intramolecular disulfide tumor cells in skin subjected to microscopically- bond formed between the Cys residues. The Cys controlled surgery.